Home / Stocks / Piramal Pharma Limited
PPLPHARMA

Piramal Pharma Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹239.65

Change

+0.7 (0.29%)

Open

₹238.0

Prev. Close

₹238.95

Day High

₹240.95

Day Low

₹235.33

Volume Analysis

Traded

1,897,130

Delivered

891,924

Delivery %

47.01%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Low return on equity (-3.83%)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹247.57 ₹244.26 ₹241.95 ₹238.64 ₹236.33 ₹233.02 ₹230.71
Fibonacci ₹244.26 ₹242.11 ₹240.79 ₹238.64 ₹236.49 ₹235.17 ₹233.02
Camarilla ₹241.2 ₹240.68 ₹240.17 ₹238.64 ₹239.13 ₹238.62 ₹238.1

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+41.07%

1 Week

-2.21%

1 Month

+25.35%

3 Months

+12.16%

6 Months

+36.45%

1 Year

+26.37%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-2.34%

Net margin -2.14% × asset turnover 0.48x × equity multiplier 2.28x

Company Overview

Sector

Healthcare

Market Cap

₹32,557 Cr

ROE

-3.83%

Book Value

₹61.2

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Piramal Pharma Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 53/100. The strongest factor is Momentum (96/100), while Business Quality (30/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-3.83%). FII holding has been falling.

TopFund Score — Fundamentals Quality

53/100 — Average

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

75

Growth

37

Valuation

50

Cash Flow

50

Corporate Governance

48

Momentum

96

Institutional Ownership

51

Business Quality

30

Risk & Volatility

58

Liquidity

65

From Screener.in

  • −Stock is trading at 4.00 times its book value
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of 7.03% over past five years.
  • −Company has a low return on equity of -0.88% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

HDFC Mutual Fund reduced Piramal Pharma holding from 7.015% to 4.988% on October 28, 2026.

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 2015

Details of Earning call Transcript held on 28th October 2026.

Audio recording of 28 October 2026 results conference call for Q2 and half year ended 30 September 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 1,911 1,959 2,552 1,951 2,242 2,204 2,754 1,934 2,044 2,140 2,752 2,270 2,617
Expenses + 1,646 1,690 2,022 1,747 1,900 1,866 2,193 1,827 1,885 1,944 2,291 2,075 2,268
Operating Profit 266 268 530 204 342 338 561 107 159 196 461 195 349
OPM % 13.9% 13.7% 20.76% 10.48% 15.24% 15.32% 20.37% 5.52% 7.76% 9.15% 16.74% 8.6% 13.33%
Other Income + 68 43 8 42 78 29 58 98 80 12 -116 109 54
Interest 110 106 114 107 108 103 104 86 82 89 83 88 88
Depreciation 185 186 196 185 192 197 243 197 203 213 218 224 233
Profit before tax 40 19 227 -45 120 67 273 -79 -46 -94 43 -7 82
Tax % 87.31% 47.78% 55.48% 96.63% 81.19% 94.49% 43.73% 3.39% 114.85% 45.1% 120.53% 830.16% 93.84%
Net Profit + 5 10 101 -89 23 4 154 -82 -99 -136 -9 -69 5
EPS in Rs 0 0 1 -1 0 0 1 -1 -1 -1 0 -1 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 11 14 18 12 17 13 8 -1 -9 -3 0 17 28

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 6,315 6,559 7,082 8,171 9,151 8,869 9,779
Expenses + 4,887 5,609 6,453 6,974 7,706 7,947 8,578
Operating Profit 1,428 950 629 1,197 1,445 922 1,200
OPM % 23.0% 14.0% 9.0% 15.0% 16.0% 10.0% 12.0%
Other Income + 230 319 272 172 208 74 59
Interest 163 198 344 448 422 341 348
Depreciation 545 586 677 741 816 831 888
Profit before tax 949 485 -120 179 415 -176 23
Tax % 12.0% 22.0% 55.0% 90.0% 78.0% 85.0% —
Net Profit + 835 376 -186 18 91 -326 -209
EPS in Rs — — -2 0 1 -2 -2
Dividend Payout % 0.0% 18.0% 0.0% 82.0% 20.0% 0.0% —
Sales growth — 4 8 15 12 -3 9

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 4,610 5,511 5,580 6,588 6,801 6,835 6,814
Borrowings + 3,025 4,128 5,637 4,710 4,856 5,675 5,873
Other Liabilities + 2,047 1,781 1,893 2,461 2,447 3,770 4,522
Total Liabilities 10,677 12,605 14,303 15,083 15,429 17,607 18,537
Fixed Assets + 6,105 6,879 7,469 7,990 8,133 8,684 9,483
CWIP 627 1,172 1,419 1,116 977 1,100 966
Investments 123 267 639 385 291 437 434
Other Assets + 3,822 4,286 4,777 5,592 6,028 7,386 7,655
Total Assets 10,677 12,605 14,303 15,083 15,429 17,607 18,537
Equity Capital 995 1,186 1,193 1,323 1,324 1,327 1,328

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 598 766 484 1,005 892 1,653
Cash from Investing Activity + -4,464 -1,737 -1,334 -416 -488 -820
Cash from Financing Activity + 3,977 794 818 -422 -441 -39
Net Cash Flow 110 -177 -32 166 -37 794
Free Cash Flow -5 -91 -461 294 233 776
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 52 98 107 97 85 202

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 35.02% → 34.8%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Others 0.38% 0.37% 0.47% 0.45% 0.4% 0.34% 0.57% 0.51% 0.44% 0.34% 0.48% 0.4%
Public 22.41% 21.89% 20.2% 19.06% 18.85% 18.42% 19.46% 19.46% 19.35% 19.01% 37.62% 36.72%
Promoters 35.02% 35.02% 34.94% 34.94% 34.94% 34.94% 34.85% 34.85% 34.85% 34.85% 34.8% 34.8%
FII 32.51% 30.58% 31.41% 31.73% 31.68% 31.49% 30.86% 30.27% 29.66% 30.17% 12.51% 13.65%
DII 9.68% 12.12% 12.95% 13.8% 14.09% 14.78% 14.25% 14.89% 15.68% 15.61% 14.57% 14.43%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Piramal Pharma Limited (this stock) 32,557 — 4.0 -3.83%
Acutaas Chemicals Limited 32,281 73.5 17.37 24.0%
Wockhardt Limited 32,944 82.4 6.39 6.11%
Krishna Inst Of Med Sci L 31,903 157.0 8.11 11.3%
Dr. Lal Path Labs Ltd. 33,582 55.5 12.2 22.3%
Rubicon Research Limited 27,764 85.5 19.59 27.0%
Narayana Hrudayalaya Ltd. 37,889 41.8 7.57 20.5%

Which Mutual Funds Hold Piramal Pharma Limited?

Frequently Asked Questions about Piramal Pharma Limited

Community Sentiment

What are other investors saying about Piramal Pharma Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.